You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What is the current cost of COPD therapies?

30 day acquisition cost: COPD therapies [1].

List price: maintenance therapies for the treatment of COPD

Please note: All formoterol preparations are assumed to be dosed at 12mcg twice a day. Seretide Accuhaler 500/50mg(1bd)+Spiriva Handihaler 18mcg(1od) is used as a comparison for triple therapy as this is the most commonly prescribed triple therapy combination[3]. This information is sensitive to price changes; drug costs and information for currently available COPD therapies were last updated in January 2017[1]. Prescribing decisions should not be based on cost alone. You should refer to the SPC[2] of each medicine for further information such as indications, contraindications, precautions and adverse events[2].

For appropriate COPD patients:

Relvar Ellipta

See how Relvar can impact your budget

Cost calculator

Incruse and Relvar Ellipta

See how Incruse + Relvar can impact your budget

Cost calculator

What potential cost savings could the Ellipta portfolio offer in your locality?

To discuss potential cost savings available in your locality, please contact us via the ‘HOC: on-Demand’’ service available through this webpage.
 

Download the 30 day drug acquisition cost information for COPD medicines

 

References:

  1. Monthly Index of Medical Specialities Online. Available at: http://www.mims.co.uk/ [Accessed January 2017]
  2. Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/ [Accessed January 2017]
  3. Patient data, IMS Information Solutions UK Ltd, June 2016

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Relvar, Anoro, Incruse, Ellipta, Seretide, Accuhaler and Evohaler are registered trademarks of the GlaxoSmithKline group of companies